You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 10, 2026

Claims for Patent: 11,633,377

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,633,377

Title:	Treatment of circadian rhythm disorders
Abstract:	Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s):	Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Assignee:	Vanda Pharmaceuticals Inc
Application Number:	US17/169,928
Patent Claims:	1. In a method of administering tasimelteon to an individual, the improvement comprising: selecting for such administration an individual having a cortisol circadian rhythm that is not entrained to the individual's day/night cycle. 2. The improvement of claim 1, wherein administering tasimelteon includes administering between about 10 mg and about 100 mg of tasimelteon. 3. The improvement of claim 1, wherein administering tasimelteon includes administering between about 20 mg and about 50 mg of tasimelteon. 4. The improvement of claim 1, wherein administering includes administering 20 mg of tasimelteon. 5. The improvement of claim 1, wherein administering includes administering 20 mg of tasimelteon once daily before the individual's bedtime. 6. The improvement of claim 5, wherein administering includes administering the 20 mg of tasimelteon 0.5 hour to 1.5 hour before the individual's bedtime. 7. The improvement of claim 5, wherein administering includes administering the 20 mg of tasimelteon one hour before the individual's bedtime. 8. The improvement of claim 1, wherein the individual is light perception impaired (LPI). 9. The improvement of claim 1, wherein the individual is totally blind. 10. The improvement of claim 1, wherein the individual suffers from Non-24-Hour Sleep-Wake Disorder. 11. The improvement of claim 1, further comprising: selecting for such administration an individual having a melatonin circadian rhythm that is not entrained to the individual's day/night cycle.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.